A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration
نویسندگان
چکیده
BACKGROUND There is a dearth of patient, preference-based cost-effectiveness analyses evaluating genetic testing for neovascular age-related macular degeneration (NVAMD). METHODS A Value-Based Medicine, 12-year, combined-eye model, cost-utility analysis evaluated genetic testing of Category 3 AMD patients at age 65 for progression to NVAMD. The benefit of genetic testing was predicated upon the fact that early-treatment ranibizumab therapy (baseline vision 20/40-20/80) for NVAMD confers greater patient value than late-treatment (baseline vision ≤20/160). Published genetic data and MARINA Study ranibizumab therapy data were utilized in the analysis. Patient value (quality-of-life gain) and financial value (2012 US real dollar) outcomes were discounted at 3 % annually. RESULTS Genetic testing-enabled, early-treatment ranibizumab therapy per patient conferred mean 20/40-1 vision, a 0.845 QALY gain and 14.1 % quality-of-life gain over sham therapy. Late-treatment ranibizumab therapy conferred mean 20/160+2 vision, a 0.250 QALY gain and 4.2 % quality-of-life gain over sham therapy. The gain from early-treatment over late-treatment was 0.595 QALY (10.0 % quality-of-life gain). The per-patient cost for genetic testing/closer monitoring was $2205 per screened person, $2.082 billion for the 944,000 estimated new Category 3 AMD patients annually. Genetic testing/monitoring costs per early-treatment patient totaled $66,180. Costs per early-treatment patient included: genetic testing costs: $66,180 + direct non-ophthalmic medical costs: -$40,914 + caregiver costs: -$172,443 + employment costs: -$14,098 = a net societal cost saving of $160,582 per early treatment patient. When genetic screening facilitated an incremental 12,965 (8.0 %) of the 161,754, new annual NVAMD patients aged ≥65 in the US to undergo early-treatment ranibizumab therapy, each additional patient treated accrued an overall, net financial gain for society of $160,582. Genetic screening was cost-effective, using World Health Organization criteria, when it enabled an incremental 4.1 % (6634) of 161,754 annual NVAMD patients ≥65 years to receive early-treatment ranibizumab therapy. CONCLUSIONS Genetic screening-enabled, early-treatment ranibizumab therapy for NVAMD is cost-effective if it enables an incremental 4.1 % of the annual US cohort of new-onset NVAMD patients ≥65 to undergo early-treatment with ranibizumab.
منابع مشابه
The goal of value-based medicine analyses: comparability. The case for neovascular macular degeneration.
PURPOSE To evaluate the comparability of articles in the peer-reviewed literature assessing the (1) patient value and (2) cost-utility (cost-effectiveness) associated with interventions for neovascular age-related macular degeneration (ARMD). METHODS A search was performed in the National Library of Medicine database of 16 million peer-reviewed articles using the key words cost-utility, cost-...
متن کاملA value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
OBJECTIVE To assess the conferred value and average cost-utility (cost-effectiveness) for intravitreal ranibizumab used to treat occult/minimally classic subfoveal choroidal neovascularization associated with age-related macular degeneration (AMD). DESIGN Value-based medicine cost-utility analysis. PARTICIPANTS MARINA (Minimally Classic/Occult Trial of the Anti-Vascular Endothelial Growth F...
متن کاملThe comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
BACKGROUND To compare a near decade of follow-up, newer control cohort data, use of both the societal and third party insurer cost perspectives, and integration of unilateral/bilateral therapy on the comparative effectiveness and cost-effectiveness of intravitreal ranibizumab therapy for neovascular, age-related macular degeneration (AMD). METHODS Value-Based Medicine®, 12-year, combined-eye ...
متن کاملMeasurement of Choroidal Neovascular Area in Age-Related Macular Degeneration using Modified Otsu’s Thresholding Method
Introduction: Age-related Macular Degeneration (AMD) is one of the most important causes of irreversible blindness in the developed world and prevents the affected person from performing simple tasks such as reading, driving and facial recognition. In the AMD, new blood vessels grow underneath the retina in a process called choroidal neovascularisation (CNV). There ...
متن کاملVALUE BASED OPHTHALMOLOGY Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration
Background/aim: Age related macular degeneration (AMD) is the leading cause of severe vision impairment and blindness in older people throughout the developed world and currently affects around 420 000 UK citizens. Choroidal neovascularisation (CNV) is treatable with photodynamic therapy (PDT) but is expensive at over £1200 per treatment. The aim of this study was to assess the cost utility of ...
متن کامل